Deals Of The Week: Novartis/Genoptix, Amgen/BioVex, Ligand/Cydex
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
You may also be interested in...
Pfizer doesn't exactly do things by halves. Two years after pulling off the sector's biggest merger, it now appears to be carrying out the largest-scale – and most ambitious – academic tie-up yet.
Tapping into the interplay between gut microbiota and an underappreciated subset of T cells could lead to therapies in a range of diseases.
Higher success rates in rare cancers, where biomarkers can better direct therapy, characterize the oncology treatment landscape. Deal-making is favoring alliances over acquisitions as drugmakers focus on establishing the clinical benefit of new targets, particularly for rare indications.